learn SCUBE3
a signaling molecule from dermal papilla cells being actively researched
Search
forLearn
5 / 801 resultslearn Tricopper peptides
learn copper tripeptide-1
learn enoxolone
learn KX-826
Research
5 / 1000+ results
research 252 Follicle dermal papilla cells undergo chromatin remodelling processes in vivo and in vitro
Hair follicle cells change their DNA packaging during growth cycles and when grown in the lab.
research Signal integrator function of CXXC5 in Cancer
CXXC5 can both suppress and promote cancer, making it a complex target for treatment.
research CXXC5: A novel regulator and coordinator of TGF-β, BMP and Wnt signaling
CXXC5 is a protein that controls cell growth and healing processes, and changes in its activity can lead to diseases like cancer and hair loss.
research 250 Sweat glands shrink upward with aging, causing dermal layer defects that lead to loss of skin elasticity and wrinkling-establishment of 3D imaging method for skin appendages
Aging causes sweat glands to shrink and move upward, leading to less elastic skin and more wrinkles.
research 254 WITHDRAWN
Aging causes sweat glands to shrink, leading to skin issues, and blue light can help hair grow.
Community Join
5 / 1000+ resultscommunity Alpha plus from Anagenica - 25%CB???
A user ordered Alpha Plus from Anagenica, expecting it to contain specific percentages of Fin, Estradiol, Minoxidil, and CB0301. However, the received product's label showed different percentages, including a surprising 25% CB, leading the user to question its safety and accuracy.
community Expectations control for SCUBE3
SCUBE3, a protein linked to hair growth in moles, was discovered over 25 years ago and is being developed by Amplifica for potential hair loss treatment. Concerns exist about SCUBE3's association with cancer, as it is a protein that promotes cell growth, which could potentially trigger cancer development if used for hair growth therapy.
community SCUBE 3 (the last hair bender)
SCUBE3 and Amplifica's progress in hair loss treatment is being discussed, with inquiries about their current status and clinical trials. No specific updates or new information are provided in the conversation.
community When will Breezula be released and how does it compare to KX-826?
Breezula (clascoterone) is expected to be available by late 2026, showing good long-term results with minimal side effects. KX-826 (pyrilutamide) acts faster but is still in earlier development stages.
community cb-03-01 research chem (winlevi/clascoterone cream)
The user is considering using CB or clascoterone for hair loss, potentially as an alternative to RU. They're also contemplating asking a dermatologist for topical clascoterone cream to apply to their temple.